1. Scrip
  2. >>Business
  3. >>Start-Ups & SMEs

Sanofi Sunrise Co. MyoKardia Sets Heart On Untapped Cardiomyopathy Market

 
• By Lucie Ellis-Taitt

Emerging Company Profile: MyoKardia, a company backed by Sanofi's Sunrise initiative, has big development plans for the first therapeutic treatment targeting the root cause of hypertrophic cardiomyopathy – a chronic, progressive form of heart failure.

EmergingCompanyProfiles_1200px

MyoKardia Inc., a company kick-started by the investment arm of French big pharma Sanofi, believes it could have the first therapeutic product in its pipeline for the underlying biomechanical cause of genetic cardiomyopathy.

The company, based in San Francisco, is targeting two of the most common forms of genetic cardiomyopathies: hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM),

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Start-Ups & SMEs

More from Business

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By Andy Smith

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.